Key Takeaways:
- Sanofi opened the Sanofi Toronto Vaccine Facility, a $925 million facility in Toronto to produce high-dose flu vaccines locally.
- Government funding provided $470 million to boost Canada’s domestic pandemic preparedness.
- Commercial production starts in 2027 and will create 300 skilled biomanufacturing jobs.
Sanofi inaugurated a $925 million flu vaccine facility in North York on Sept. 16, adding domestic manufacturing capacity, supporting pandemic preparedness and creating about 300 skilled jobs.
Sanofi Expands Domestic Vaccine Production
The Charles Best Building, located at Sanofi’s 52-acre Toronto campus, will manufacture Fluzone High-Dose, an influenza vaccine for adults 65 and older. The Sanofi Toronto Vaccine Facility covers 263,000 square feet and includes manufacturing, formulation, filling, and packaging operations.
Sanofi said the investment includes $415 million from the federal government and $55 million from Ontario. The company described it as the largest single investment in a biomanufacturing facility in Canadian history.
“Today marks a strategic milestone for Sanofi,” said James Guy, Sanofi’s Canada country lead. He said the company remains committed to working with governments to provide Canadians with reliable access to medicines and vaccines.
Facility Supports Pandemic Preparedness
The Sanofi Toronto Vaccine Facility is designed to add end-to-end influenza vaccine manufacturing capacity in Canada. Sanofi said the expansion will help strengthen the country’s ability to respond to future influenza pandemics and reduce reliance on international supply chains.
Ontario Deputy Premier and Health Minister Sylvia Jones said the investment will support vaccine access and strengthen the province’s biomanufacturing sector. “The new Sanofi vaccine manufacturing facility in Toronto will deliver hundreds of good-paying jobs,” Jones said.
Toronto Mayor Olivia Chow said the project strengthens the city’s role in health care and medical manufacturing. “This investment reinforces Toronto as a leader in the medical and healthcare sector,” Chow said.
Production Set To Begin In 2027
The Charles Best Building broke ground in 2021 and is now fully operational, but commercial production remains subject to regulatory approval. Sanofi expects manufacturing to begin in early 2027 ahead of the 2027-28 flu season.
The project is expected to create about 300 highly skilled jobs in advanced biomanufacturing, including positions in production, quality, and skilled trades. Sanofi said the expansion builds on more than a century of operations in Canada.
Sanofi’s Toronto campus already serves as a major vaccine research and manufacturing center, with vaccines produced there distributed to more than 60 countries. The company says it has invested more than $1.5 billion in pharmaceutical research in Canada over the past decade.
The new building at the Sanofi Toronto Vaccine Facility is named for Dr. Charles Best, the Canadian medical researcher who co-discovered insulin and worked at the former Connaught Laboratories site where Sanofi’s Toronto campus now operates.
Visit more of our news! Healthcare 360 Magazine
